🔎 Trials Near Me

Akèy › Kansè Metastatik › Ohio › Columbus

Etid klinik pou Kansè Metastatik nan Columbus, OH

27 etid pou Kansè Metastatik ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
  • Mount Carmel East Hospital, Columbus
  • Columbus Oncology and Hematology Associates Inc, Columbus
  • ak 13 plis
Tout laj · Tout sèks · Mizajou Oct 5, 2026 · NCT05564377

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Ap rekriteFaz 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05372614

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Ap rekriteFaz 1
  • ALX Center 10, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT07085091

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Ap rekriteFaz 2/3
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06943755

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Ap rekriteFaz 1/2
  • Ohio State University, Columbus
Laj 12 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT05118789

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Ap rekriteFaz 3
  • The Mark H Zangmeister Center, Columbus
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Hilliard · 10 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07213804

SLV-154 Treatment of Advanced Cancers

Ap rekriteFaz 1
  • The James Outpatient Care West Center, Columbus
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06771219

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Ap rekriteFaz 3
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ap rekriteFaz 3
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1/2
  • Clinical Study Site, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT07335497

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

Ap rekriteFaz 1
  • Ohio State University Hospital, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06561685

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Ap rekriteFaz 3
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Ap rekriteFaz 2
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06311214

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

Ap rekriteFaz 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05687136

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ap rekriteFaz 2
  • Ohio State University, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

Ap rekriteFaz 1
  • The Ohio State University (OSU), Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

Ap rekriteFaz 1
  • Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT05687110

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Ap rekriteFaz 3
  • Research Site, Columbus
  • Research Site, Hilliard · 10 mi lwen
Laj 18 ak plis · Fanm · Mizajou Jul 29, 2026 · NCT07044336

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Ap rekriteFaz 1
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Gason · Mizajou Jul 9, 2026 · NCT07103018

A Study of LY4175408 in Participants With Advanced Cancer

Ap rekriteFaz 1
  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Ap rekriteFaz 1/2
  • OSU Brain & Spine Hospital, Columbus
Laj 12 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT05384626

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Ap rekriteFaz 3
  • Stefanie Spielman Comprehensive Breast Center at Olentangy River Road, Columbus
Laj 18 ak plis · Tout sèks · Mizajou May 18, 2026 · NCT06757634

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Ap rekriteFaz 3
  • Ohio State University, James Cancer Hospital and Solove Research Institute, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Apr 9, 2026 · NCT06064877

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Ap rekriteFaz 1
  • OSU Brain and Spine Hospital, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Feb 25, 2026 · NCT06521554

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

Ap rekriteFaz 3
  • The Ohio State University Comprehensive Cancer Center, Columbus
Laj 18 ak plis · Tout sèks · Mizajou Feb 6, 2026 · NCT06127407

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Columbus
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

Etid Kansè Metastatik nan lòt vil

Lòt etid nan Columbus

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.